NZ587928A - Azetidine and cyclobutane derivatives as jak inhibitors - Google Patents

Azetidine and cyclobutane derivatives as jak inhibitors

Info

Publication number: NZ587928A
Authority: NZ; New Zealand
Prior art keywords: disease; pyrrolo; pyrazol; pyrimidin; compound
Prior art date: 2008-03-11

Application number

NZ587928A

Other languages

English (en)

Inventor

James D Rodgers

Stacey Shepard

Yun-Long Li

Jiacheng Zhou

Pingli Liu

David Meloni

Michael Xia

Original Assignee

Incyte Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-11

Filing date

2009-03-10

Publication date

2012-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ587928(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-03-10 Application filed by Incyte Corp filed Critical Incyte Corp

2012-08-31 Publication of NZ587928A publication Critical patent/NZ587928A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60Q—ARRANGEMENT OF SIGNALLING OR LIGHTING DEVICES, THE MOUNTING OR SUPPORTING THEREOF OR CIRCUITS THEREFOR, FOR VEHICLES IN GENERAL
- B60Q3/00—Arrangement of lighting devices for vehicle interiors; Lighting devices specially adapted for vehicle interiors
- B60Q3/70—Arrangement of lighting devices for vehicle interiors; Lighting devices specially adapted for vehicle interiors characterised by the purpose
- B60Q3/76—Arrangement of lighting devices for vehicle interiors; Lighting devices specially adapted for vehicle interiors characterised by the purpose for spotlighting, e.g. reading lamps
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60Q—ARRANGEMENT OF SIGNALLING OR LIGHTING DEVICES, THE MOUNTING OR SUPPORTING THEREOF OR CIRCUITS THEREFOR, FOR VEHICLES IN GENERAL
- B60Q3/00—Arrangement of lighting devices for vehicle interiors; Lighting devices specially adapted for vehicle interiors
- B60Q3/80—Circuits; Control arrangements
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S362/00—Illumination
- Y10S362/80—Light emitting diode
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S362/00—Illumination
- Y10S362/802—Position or condition responsive switch

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Mechanical Engineering (AREA)
Cardiology (AREA)
Hematology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Obesity (AREA)
Transplantation (AREA)
Surgery (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NZ587928A 2008-03-11 2009-03-10 Azetidine and cyclobutane derivatives as jak inhibitors NZ587928A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US3566208P	2008-03-11	2008-03-11
US14498209P	2009-01-15	2009-01-15
PCT/US2009/036635 WO2009114512A1 (en)	2008-03-11	2009-03-10	Azetidine and cyclobutane derivatives as jak inhibitors

Publications (1)

Publication Number	Publication Date
NZ587928A true NZ587928A (en)	2012-08-31

Family

ID=40591836

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NZ587928A NZ587928A (en)	2008-03-11	2009-03-10	Azetidine and cyclobutane derivatives as jak inhibitors

Country Status (44)

Country	Link
US (3)	US8158616B2 (sl)
EP (1)	EP2288610B8 (sl)
JP (2)	JP5275371B2 (sl)
KR (2)	KR101240882B1 (sl)
CN (2)	CN103788098A (sl)
AR (1)	AR070828A1 (sl)
AU (1)	AU2009223640B2 (sl)
BR (1)	BRPI0909040B8 (sl)
CA (1)	CA2718271C (sl)
CL (1)	CL2009000576A1 (sl)
CO (1)	CO6290658A2 (sl)
CY (2)	CY1118176T1 (sl)
DK (1)	DK2288610T3 (sl)
DO (2)	DOP2010000270A (sl)
EA (1)	EA017218B1 (sl)
EC (1)	ECSP10010475A (sl)
ES (1)	ES2602577T3 (sl)
HK (1)	HK1149005A1 (sl)
HN (1)	HN2010001761A (sl)
HR (1)	HRP20161390T1 (sl)
HU (2)	HUE029767T2 (sl)
IL (1)	IL208023A (sl)
LT (2)	LT2288610T (sl)
LU (1)	LUC00027I2 (sl)
MA (1)	MA32219B1 (sl)
MX (1)	MX2010010012A (sl)
MY (1)	MY165582A (sl)
NL (1)	NL300886I2 (sl)
NO (1)	NO2017033I1 (sl)
NZ (1)	NZ587928A (sl)
PA (1)	PA8819201A1 (sl)
PE (2)	PE20091712A1 (sl)
PL (1)	PL2288610T3 (sl)
PT (1)	PT2288610T (sl)
RS (1)	RS55263B1 (sl)
SG (1)	SG191660A1 (sl)
SI (1)	SI2288610T1 (sl)
SV (1)	SV2010003662A (sl)
TN (1)	TN2010000415A1 (sl)
TW (1)	TWI444382B (sl)
UA (1)	UA101493C2 (sl)
UY (1)	UY31705A1 (sl)
WO (1)	WO2009114512A1 (sl)
ZA (1)	ZA201006000B (sl)

Families Citing this family (289)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005105814A1 (en) *	2004-04-28	2005-11-10	Incyte Corporation	Tetracyclic inhibitors of janus kinases
LT2426129T (lt) *	2005-12-13	2017-02-10	Incyte Holdings Corporation	Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
WO2008079965A1 (en)	2006-12-22	2008-07-03	Incyte Corporation	Substituted heterocycles as janus kinase inhibitors
RS54878B1 (sr)	2007-06-13	2016-10-31	Incyte Holdings Corp	Kristalne soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropionitril
CL2008001709A1 (es)	2007-06-13	2008-11-03	Incyte Corp	Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
US8309718B2 (en) *	2007-11-16	2012-11-13	Incyte Corporation	4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
CN102083830B (zh) *	2008-03-24	2014-11-12	梅迪维新技术公司	吡啶并[3,4-b]吲哚和应用方法
KR20110033223A (ko) *	2008-06-20	2011-03-30	제넨테크, 인크.	트리아졸로피리딘 ｊａｋ 억제제 화합물 및 방법
BRPI0909945A2 (pt) *	2008-06-20	2015-07-28	Genentech Inc	"composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
CL2009001884A1 (es) *	2008-10-02	2010-05-14	Incyte Holdings Corp	Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JOP20190231A1 (ar)	2009-01-15	2017-06-16	Incyte Corp	طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
WO2010135650A1 (en)	2009-05-22	2010-11-25	Incyte Corporation	N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
UA106078C2 (uk)	2009-05-22	2014-07-25	Інсайт Корпорейшн	3-[4-(7H-ПІРОЛО[2,3-d]ПІРИМІДИН-4-ІЛ)-1H-ПІРАЗОЛ-1-ІЛ]ОКТАН- АБО ГЕПТАННІТРИЛ ЯК JAK-ІНГІБІТОРИ
WO2011028685A1 (en)	2009-09-01	2011-03-10	Incyte Corporation	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
KR101805936B1 (ko) *	2009-10-09	2017-12-07	인사이트 홀딩스 코포레이션	3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
JP5858434B2 (ja) *	2010-02-18	2016-02-10	インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅＨｏｌｄｉｎｇｓＣｏｒｐｏｒａｔｉｏｎ	Ｊａｎｕｓキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体
AU2015205858B2 (en) *	2010-03-10	2017-04-13	Incyte Holdings Corporation	Piperidin-4-yl azetidine derivatives as jak1 inhibitors
MX364636B (es) *	2010-03-10	2019-05-03	Incyte Corp	Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
NZ603446A (en)	2010-04-14	2014-05-30	Array Biopharma Inc	5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
SI2574168T1 (sl)	2010-05-21	2016-07-29	Incyte Holdings Corporation	Topična formulacija zaviralca jak
US9034884B2 (en)	2010-11-19	2015-05-19	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
EA036970B1 (ru) *	2010-11-19	2021-01-21	Инсайт Холдингс Корпорейшн	Применение {1-{1-[3-фтор-2-(трифтометил)изоникотиноил] пиперидин-4-ил}-3-[4-(7h-пирроло[2,3-d]пиримидин-4-ил)-1н-пиразол-1-ил]азетидин-3-ил}ацетонитрила для лечения заболеваний, связанных с активностью jak1
SG190839A1 (en)	2010-11-19	2013-07-31	Incyte Corp	Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
SG190957A1 (en) *	2010-12-01	2013-07-31	Nissan Chemical Ind Ltd	Pyrazole compounds having therapeutic effect on multiple myeloma
EP2675451B9 (en)	2011-02-18	2017-07-26	Novartis Pharma AG	mTOR/JAK INHIBITOR COMBINATION THERAPY
EP2675459A4 (en)	2011-02-18	2014-08-06	Medivation Technologies Inc	COMPOUNDS AND METHODS FOR TREATING DIABETES
JP5938422B2 (ja) *	2011-03-08	2016-06-22	ジーイー・ヘルスケア・リミテッド	Ｐｅｔ前駆体の製造
AU2012273164B2 (en) *	2011-06-20	2015-05-28	Incyte Holdings Corporation	Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
JP2014521725A (ja)	2011-08-10	2014-08-28	ノバルティス・ファルマ・アクチェンゲゼルシャフト	ＪＡＫＰＩ３Ｋ／ｍＴＯＲ併用療法
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
JP6014149B2 (ja) *	2011-09-22	2016-10-25	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	ヤヌスキナーゼ阻害剤としての非環式シアノエチルピラゾール
CN107898790B (zh)	2011-11-30	2024-06-21	埃默里大学	用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
US20130310340A1 (en)	2012-05-16	2013-11-21	Rigel Pharmaceuticals, Inc.	Method of treating muscular degradation
AR091079A1 (es)	2012-05-18	2014-12-30	Incyte Corp	Derivados de pirrolopirimidina y pirrolopiridina sustituida con piperidinilciclobutilo como inhibidores de jak
SG10201805807PA (en)	2012-06-26	2018-08-30	Del Mar Pharmaceuticals	Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
RU2666538C2 (ru) *	2012-08-02	2018-09-11	НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л.	Замещенные пирролы, активные в качестве ингибиторов киназ
MX361499B (es)	2012-08-17	2018-12-06	Concert Pharmaceuticals Inc	Baricitinib deuterado.
AR093308A1 (es)	2012-11-01	2015-05-27	Incyte Corp	Derivados triciclicos fusionados de tiofeno como inhibidores de jak
JP2015537030A (ja)	2012-11-15	2015-12-24	インサイト・コーポレイションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	ルキソリチニブの徐放性投薬形態
CN103965114B (zh) *	2013-01-28	2016-01-06	苏州泽璟生物制药有限公司	氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物
KR102366356B1 (ko)	2013-03-06	2022-02-23	인사이트 홀딩스 코포레이션	Jak 저해제를 제조하기 위한 방법 및 중간생성물
WO2014146249A1 (en) *	2013-03-19	2014-09-25	Merck Sharp & Dohme Corp.	Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors
WO2014168986A1 (en)	2013-04-08	2014-10-16	Brown Dennis M	Therapeutic benefit of suboptimally administered chemical compounds
EA036448B1 (ru) *	2013-05-17	2020-11-11	Инсайт Корпорейшн	Производные бипиразола в качестве ингибиторов jak
CN105764501A (zh)	2013-07-26	2016-07-13	现代化制药公司	改善比生群治疗效益的组合物
EP3721873A1 (en) *	2013-08-07	2020-10-14	Incyte Corporation	Sustained release dosage forms for a jak1 inhibitor
EA201690421A1 (ru)	2013-08-20	2016-06-30	Инсайт Корпорейшн	Положительный эффект в форме увеличения продолжительности жизни у больных с солидными опухолями с повышенными уровнями c-реактивного белка
WO2015095492A1 (en)	2013-12-19	2015-06-25	Incyte Corporation	Tricyclic heterocycles as bet protein inhibitors
SG10201806846RA (en)	2014-02-13	2018-09-27	Incyte Corp	Cyclopropylamines as lsd1 inhibitors
PH12020552066A1 (en)	2014-02-13	2022-05-11	Incyte Corp	Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en)	2014-02-13	2016-12-27	Incyte Corporation	Cyclopropylamines as LSD1 inhibitors
EP3392244A1 (en)	2014-02-13	2018-10-24	Incyte Corporation	Cyclopropylamines as lsd1 inhibitors
PL3110409T3 (pl)	2014-02-28	2018-12-31	Incyte Corporation	Inhibitory jak1 do leczenia zespołów mielodysplastycznych
US9340540B2 (en)	2014-02-28	2016-05-17	Nimbus Lakshmi, Inc.	TYK2 inhibitors and uses thereof
EP3134412A1 (en)	2014-03-28	2017-03-01	Sun Pharmaceutical Industries Limited	Amorphous form of baricitinib
BR112016025427A2 (pt)	2014-04-30	2017-08-15	Incyte Corp	processos de preparação de um inibidor de jak1 e formas do mesmo
EP3136857A4 (en)	2014-05-01	2017-09-20	Sun Pharmaceutical Industries Limited	Crystalline form of baricitinib
WO2015184305A1 (en)	2014-05-30	2015-12-03	Incyte Corporation	TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
WO2016007722A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695168B2 (en)	2014-07-10	2017-07-04	Incyte Corporation	Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
WO2016007727A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201613925A (en)	2014-07-10	2016-04-16	Incyte Corp	Imidazopyrazines as LSD1 inhibitors
ES2921875T3 (es)	2014-08-11	2022-09-01	Acerta Pharma Bv	Combinaciones terapéuticas de un inhibidor BTK, un inhibidor PD-1 y/o un inhibidor PD-L1
WO2016024232A1 (en)	2014-08-11	2016-02-18	Acerta Pharma B.V.	Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
SI3179991T1 (sl)	2014-08-11	2022-04-29	Acerta Pharma B.V.	Terapevtske kombinacije zaviralca BTK in zaviralca BCL-2
AU2015303835B2 (en)	2014-08-12	2020-04-09	Monash University	Lymph directing prodrugs
TWI679205B (zh)	2014-09-02	2019-12-11	日商日本新藥股份有限公司	吡唑并噻唑化合物及醫藥
CN105524067A (zh) *	2014-09-28	2016-04-27	江苏柯菲平医药股份有限公司	4-取代吡咯并[2,3-d]嘧啶化合物及其用途
EP3227298A4 (en) *	2014-12-05	2018-05-23	Sun Pharmaceutical Industries Ltd	Process for the preparation of baricitinib and an intermediate thereof
CN105777754B (zh)	2014-12-16	2019-07-26	北京赛林泰医药技术有限公司	吡咯并嘧啶化合物
US10526350B2 (en)	2015-02-02	2020-01-07	Sun Pharmaceutical Industries Limited	Process for the preparation of baricitinib and an intermediate thereof
EP3253760A4 (en) *	2015-02-02	2018-06-20	Sun Pharmaceutical Industries Limited	Process for the preparation of baricitinib and an intermediate thereof
EP3262049B1 (en)	2015-02-27	2022-07-20	Nimbus Lakshmi, Inc.	Tyk2 inhibitors and uses thereof
CN105924444B (zh) *	2015-03-11	2019-06-18	苏州晶云药物科技股份有限公司	Jak抑制剂的晶型及其制备方法
EP3269719B1 (en) *	2015-03-11	2020-05-13	Crystal Pharmatech Co. Ltd.	Crystal form of jak inhibitor and preparation method thereof
PH12017501817B1 (en)	2015-04-03	2023-06-16	Incyte Holdings Corp	Heterocyclic compounds as lsd1 inhibitors
AR104918A1 (es) *	2015-06-19	2017-08-23	Lilly Co Eli	Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo
WO2017004134A1 (en)	2015-06-29	2017-01-05	Nimbus Iris, Inc.	Irak inhibitors and uses thereof
TWI765860B (zh)	2015-08-12	2022-06-01	美商英塞特公司	Lsd1抑制劑之鹽
TWI707852B (zh)	2015-09-02	2020-10-21	美商林伯士拉克許米公司	Tyk2 抑制劑及其用途
WO2017041139A1 (en)	2015-09-08	2017-03-16	Monash University	Lymph directing prodrugs
WO2017044720A1 (en)	2015-09-11	2017-03-16	Navitor Pharmaceuticals, Inc.	Rapamycin analogs and uses thereof
CN106554363B (zh) *	2015-09-28	2019-03-05	正大天晴药业集团股份有限公司	一种Baricitinib中间体的制备方法
AU2016342027B2 (en)	2015-10-23	2021-05-13	Navitor Pharmaceuticals, Inc.	Modulators of Sestrin-GATOR2 interaction and uses thereof
RU2601410C1 (ru) *	2015-11-13	2016-11-10	ЗАО "Р-Фарм"	{3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕТИДИН-3-ИЛ}АЦЕТОНИТРИЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС КИНАЗ
RU2603959C1 (ru) *	2015-11-13	2016-12-10	Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм")	ДИХЛОРАЦЕТАТ {3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-ПИРАЗОЛ-1-ИЛ]-1-ЭТИЛСУЛЬФОНИЛ-АЗЕТИДИН-3-ИЛ}-АЦЕТОНИТРИЛА В КАЧЕСТВЕ ИНГИБИТОРА ЯНУС КИНАЗ
CN105294699B (zh) *	2015-12-04	2019-06-11	上海勋和医药科技有限公司	巴瑞替尼的制备方法
EP3360878B9 (en) *	2015-12-11	2021-05-05	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Azetidine derivative, preparation method therefor, and use thereof
WO2017106352A1 (en)	2015-12-14	2017-06-22	Raze Therapeutics, Inc.	Caffeine inhibitors of mthfd2 and uses thereof
HU230805B1 (hu) *	2015-12-23	2018-06-28	Egis Gyógyszergyár Zrt	Eljárás és köztitermék baricitinib előállítására
HU230931B1 (hu) *	2016-01-21	2019-04-29	Egis Gyógyszergyár Zrt.	Baricitinib sók
WO2017129116A1 (zh) *	2016-01-26	2017-08-03	杭州华东医药集团新药研究院有限公司	吡咯嘧啶五元氮杂环衍生物及其应用
CN105566332B (zh) *	2016-01-29	2018-01-16	上海宣创生物科技有限公司	巴瑞克替尼三氟乙酸盐a晶型和b晶型及其制备方法
CN105601635B (zh) *	2016-02-01	2017-12-12	上海宣创生物科技有限公司	巴瑞克替尼磷酸盐的a晶型、h晶型和i晶型及其制备方法
CN105541891B (zh) *	2016-02-04	2017-11-28	东南大学	巴瑞替尼的中间体及其制备方法及由该中间体制备巴瑞替尼的方法
TWI712604B (zh)	2016-03-01	2020-12-11	日商日本新藥股份有限公司	具jak抑制作用之化合物之結晶
ES2949357T3 (es)	2016-03-09	2023-09-28	Raze Therapeutics Inc	Inhibidores de 3-fosfoglicerato deshidrogenasa y usos de los mismos
EP3884939B1 (en)	2016-03-09	2023-10-25	Raze Therapeutics, Inc.	3-phosphoglycerate dehydrogenase inhibitors and uses thereof
CN107200742A (zh) *	2016-03-18	2017-09-26	罗欣生物科技（上海）有限公司	一种巴瑞克替尼磷酸盐晶体及其制备方法
CN107226814A (zh) *	2016-03-23	2017-10-03	罗欣生物科技（上海）有限公司	一种巴瑞克替尼中间体的制备方法
US11337969B2 (en)	2016-04-08	2022-05-24	X4 Pharmaceuticals, Inc.	Methods for treating cancer
CN109414410B (zh)	2016-04-22	2022-08-12	因赛特公司	Lsd1抑制剂的制剂
CN107334738B (zh) *	2016-04-28	2021-02-09	天津科伦药物研究有限公司	一种含巴瑞克替尼的药物组合物及其制备方法和用途
JP7054529B2 (ja)	2016-06-21	2022-04-14	エックス４ファーマシューティカルズ，インコーポレイテッド	Ｃｘｃｒ４阻害剤およびその使用
US10988465B2 (en)	2016-06-21	2021-04-27	X4 Pharmaceuticals, Inc.	CXCR4 inhibitors and uses thereof
EP3472129A4 (en)	2016-06-21	2019-12-04	X4 Pharmaceuticals, Inc.	CXCR4 INHIBITORS AND USES THEREOF
WO2018019222A1 (zh) *	2016-07-26	2018-02-01	张文燕	作为jak抑制剂杂环化合物，该化合物的盐类及其治疗用途
CN106496233B (zh) *	2016-09-26	2018-05-15	东南大学	吡咯并嘧啶类化合物、其制备方法及其用途
TWI763722B (zh)	2016-10-14	2022-05-11	美商林伯士拉克許米公司	Tyk2抑制劑及其用途
JP7082120B2 (ja)	2016-10-21	2022-06-07	ニンバスラクシュミ，インコーポレイテッド	Ｔｙｋ２阻害剤およびその使用
EP3538091A4 (en)	2016-11-08	2020-06-10	Navitor Pharmaceuticals, Inc.	PHENYL AMINO PIPERIDINE MTORC INHIBITORS AND USES THEREOF
CZ2016705A3 (cs)	2016-11-11	2018-05-23	Zentiva, K.S.	Krystalické formy 2- [1-ethylsulfonyl-3- [4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) pyrazol-1-yl] azetidin-3-yl] acetonitrilových solí a jejich příprava
CN110177544A (zh)	2016-11-29	2019-08-27	普尔泰克健康有限公司	用于递送治疗剂的外泌体
EP3327020A1 (en)	2016-11-29	2018-05-30	Sandoz Ag	Citrate salts of a janus kinase (jak) inhibitor
WO2018106636A1 (en)	2016-12-05	2018-06-14	Raze Therapeutics, Inc.	Shmt inhibitors and uses thereof
RU2644155C1 (ru) *	2016-12-12	2018-02-08	Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм")	2-(3-(4-(7H-пирроло[2,3-d]пиримидин-4-ил)-1H-пиразол-1-ил)-1-(этилсульфонил)азетидин-3-ил)ацетонитрила геминафтилдисульфонат в качестве ингибитора Янус киназ
CZ2016816A3 (cs)	2016-12-21	2018-07-04	Zentiva, K.S.	Krystalické formy 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrilu s kyselinou fosforečnou a způsob jejich přípravy
CN110603261A (zh)	2016-12-23	2019-12-20	拜斯科阿迪有限公司	具有新型键结构的肽衍生物
EP3565638B8 (en)	2017-01-06	2024-04-10	BicycleRD Limited	Bicycle conjugate for treating cancer
EA039344B1 (ru) *	2017-01-19	2022-01-17	Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд.	Гетероциклическое соединение в качестве ингибитора jak и его соли и терапевтическое применение
US11524961B2 (en)	2017-01-23	2022-12-13	Shanghai Longwood Biopharmaceuticals Co., Ltd.	JAK kinase inhibitor and preparation method and use thereof
AU2018230737B2 (en)	2017-03-08	2022-09-22	Takeda Pharmaceutical Company Limited	Tyk2 inhibitors, uses, and methods for production thereof
EP3375784A1 (en)	2017-03-14	2018-09-19	Artax Biopharma Inc.	Aza-dihydro-acridone derivatives
EP3375778A1 (en)	2017-03-14	2018-09-19	Artax Biopharma Inc.	Aryl-piperidine derivatives
CN106946917B (zh) *	2017-03-20	2019-06-11	杭州科巢生物科技有限公司	一种jak抑制剂巴瑞替尼及其中间体的新合成方法
CN107176955B (zh) *	2017-03-24	2019-04-09	南京优科制药有限公司	一种巴瑞替尼的制备方法
WO2018191146A1 (en)	2017-04-10	2018-10-18	Navitor Pharmaceuticals, Inc.	Heteroaryl rheb inhibitors and uses thereof
US10912750B2 (en)	2017-04-26	2021-02-09	Navitor Pharmaceuticals, Inc.	Modulators of Sestrin-GATOR2 interaction and uses thereof
WO2018197893A1 (en)	2017-04-27	2018-11-01	Bicycletx Limited	Bicyclic peptide ligands and uses thereof
AU2018273866B2 (en)	2017-05-23	2021-09-30	Theravance Biopharma R&D Ip, Llc	Glucuronide prodrugs of Janus kinase inhibitors
DK3636647T3 (da) *	2017-06-07	2023-02-06	Sichuan Kelun Biotech Biopharmaceutical Co Ltd	Fastform af azetidinderivat og fremstillingsfremgangsmåde derfor samt anvendelse deraf
CN110799512A (zh) *	2017-06-22	2020-02-14	苏州科睿思制药有限公司	巴瑞克替尼的晶型及其制备方法
EP3645549A1 (en)	2017-06-26	2020-05-06	BicycleRD Limited	Bicyclic peptide ligands with detectable moieties and uses thereof
WO2019003249A1 (en)	2017-06-28	2019-01-03	Mylan Laboratories Limited	POLYMORPHIC FORMS OF BARICITINIB
BR112020001714A2 (pt)	2017-07-28	2020-07-21	Nimbus Lakshmi, Inc.	inibidores de tyk2 e usos dos mesmos
CN118772242A (zh)	2017-08-04	2024-10-15	拜斯科技术开发有限公司	Cd137特异性的双环肽配体
EP3668887A1 (en)	2017-08-14	2020-06-24	Bicyclerd Limited	Bicyclic peptide ligand sting conjugates and uses thereof
WO2019034868A1 (en)	2017-08-14	2019-02-21	Bicyclerd Limited	CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
EP3675838A4 (en)	2017-08-29	2021-04-21	PureTech LYT, Inc.	Lymphatic system-directing lipid prodrugs
US11883497B2 (en)	2017-08-29	2024-01-30	Puretech Lyt, Inc.	Lymphatic system-directing lipid prodrugs
EP3684366A4 (en)	2017-09-22	2021-09-08	Kymera Therapeutics, Inc.	CRBN LIGANDS AND USES OF THE LATEST
IL273432B (en)	2017-09-22	2022-09-01	Kymera Therapeutics Inc	Protein degraders and uses thereof
CN109651424B (zh) *	2017-10-11	2021-01-22	新发药业有限公司	一种7-保护基-4-(1-氢-吡唑-4-基)吡咯[2,3-d]嘧啶的合成方法
LT3697789T (lt)	2017-10-18	2021-12-10	Incyte Corporation	Kondensuoti imidazolo dariniai, pakeisti tretinėmis hidroksigrupėmis, kaip pi3k-gama inhibitoriai
SG11202002947TA (en) *	2017-11-03	2020-04-29	Aclaris Therapeutics Inc	Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same
CN113149993A (zh) *	2017-12-01	2021-07-23	北京普祺医药科技有限公司	一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
TW201924683A (zh)	2017-12-08	2019-07-01	美商英塞特公司	用於治療骨髓增生性贅瘤的低劑量組合療法
CN108129482A (zh) *	2017-12-13	2018-06-08	江苏中邦制药有限公司	一种巴瑞替尼的制备方法
WO2019126378A1 (en)	2017-12-19	2019-06-27	Ariya Therapeutics, Inc.	Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en)	2017-12-19	2023-03-21	Puretech Lyt, Inc.	Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en)	2017-12-19	2022-04-19	Puretech Lyt, Inc.	Lipid prodrugs of mycophenolic acid and uses thereof
TWI825046B (zh)	2017-12-19	2023-12-11	英商拜西可泰克斯有限公司	Epha2特用之雙環胜肽配位基
GB201721265D0 (en)	2017-12-19	2018-01-31	Bicyclerd Ltd	Bicyclic peptide ligands specific for EphA2
EP3502114A1 (en)	2017-12-20	2019-06-26	Sandoz AG	Co-crystal of an orally available janus kinase inhibitor
IL315310A (en)	2017-12-26	2024-10-01	Kymera Therapeutics Inc	Irak degraders and uses thereof
US10766900B2 (en)	2017-12-29	2020-09-08	Formosa Laboratories, Inc.	Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof
EP3737675A4 (en)	2018-01-12	2022-01-05	Kymera Therapeutics, Inc.	Crbn ligands and uses thereof
WO2019140380A1 (en)	2018-01-12	2019-07-18	Kymera Therapeutics, Inc.	Protein degraders and uses thereof
IL312674A (en)	2018-01-29	2024-07-01	Merck Patent Gmbh	GCN2 inhibitors and uses thereof
CN118005640A (zh)	2018-01-29	2024-05-10	默克专利股份有限公司	Gcn2抑制剂及其用途
AR114810A1 (es)	2018-01-30	2020-10-21	Incyte Corp	Procesos e intermedios para elaborar un inhibidor de jak
IL276725B2 (en)	2018-02-16	2024-09-01	Incyte Corp	Jak1 pathway inhibitors for the treatment of cytokine-related disorders
EP3759086A1 (en)	2018-02-27	2021-01-06	Artax Biopharma Inc.	Chromene derivatives as inhibitors of tcr-nck interaction
CN110357887B (zh) *	2018-03-26	2022-09-16	武汉誉祥医药科技有限公司	取代的7H-吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途
MA52655A (fr)	2018-03-30	2021-02-17	Incyte Corp	Biomarqueurs pour maladie cutanée inflammatoire
CN113768934A (zh)	2018-03-30	2021-12-10	因赛特公司	使用jak抑制剂治疗化脓性汗腺炎
MX2020010815A (es)	2018-04-13	2020-12-11	Incyte Corp	Biomarcadores para enfermedad de injerto contra hospedero.
SMT202200308T1 (it)	2018-04-24	2022-09-14	Vertex Pharma	Composti antiproliferazione e loro usi
US11059826B2 (en)	2018-04-24	2021-07-13	Vertex Pharmaceuticals Incorporated	Pteridinone compounds and uses thereof
CN108752254B (zh) *	2018-05-22	2021-11-02	道合(潍坊)医药技术有限公司	2-[1-(乙基磺酰基)-3-氮杂环丁亚基]乙腈的制备方法
CN112804994A (zh) *	2018-05-25	2021-05-14	卡托斯医疗公司	治疗骨髓增殖性肿瘤的方法
CN110446713B (zh) *	2018-06-06	2022-05-24	杭州澳津生物医药技术有限公司	一种吡唑嘧啶衍生物及其用途和药物组合物
KR20210021534A (ko)	2018-06-15	2021-02-26	나비토르 파마슈티칼스 인코포레이티드	라파마이신 유사체 및 이의 용도
US11180531B2 (en)	2018-06-22	2021-11-23	Bicycletx Limited	Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en)	2018-06-22	2018-08-08	Bicyclerd Ltd	Peptide ligands for binding to EphA2
US11292792B2 (en)	2018-07-06	2022-04-05	Kymera Therapeutics, Inc.	Tricyclic CRBN ligands and uses thereof
WO2020047198A1 (en)	2018-08-31	2020-03-05	Incyte Corporation	Salts of an lsd1 inhibitor and processes for preparing the same
US10548889B1 (en)	2018-08-31	2020-02-04	X4 Pharmaceuticals, Inc.	Compositions of CXCR4 inhibitors and methods of preparation and use
MA53561A (fr)	2018-09-05	2022-05-11	Incyte Corp	Formes cristallines d'un inhibiteur de phosphoinositide 3-kinase (pi3k)
JP2022500499A (ja)	2018-09-07	2022-01-04	ピクセラピューティクス，インコーポレイテッド	Ｅｉｆ４ｅ阻害剤およびその使用
CN109215136B (zh)	2018-09-07	2020-03-20	百度在线网络技术（北京）有限公司	一种真实数据增强方法、装置以及终端
CN109146898B (zh)	2018-09-07	2020-07-24	百度在线网络技术（北京）有限公司	一种仿真数据量增强方法、装置以及终端
WO2020072870A1 (en)	2018-10-05	2020-04-09	Johnson Matthey Public Limited Company	Co-crystal forms of baricitinib
CN113271940A (zh)	2018-10-15	2021-08-17	林伯士拉克许米公司	Tyk2抑制剂和其用途
TW202033198A (zh)	2018-10-17	2020-09-16	美商美國禮來大藥廠	以巴瑞克替尼(baricitinib)治療原發性膽汁性膽管炎及原發性硬化性膽管炎
JP2022512779A (ja)	2018-10-23	2022-02-07	バイスクルテクス・リミテッド	二環式ペプチドリガンドおよびその使用
JP2022505849A (ja)	2018-10-24	2022-01-14	ナビターファーマシューティカルズ，インコーポレイテッド	多形化合物およびその使用
JP7431845B2 (ja)	2018-10-31	2024-02-15	インサイト・コーポレイション	血液疾患の治療のための併用療法
JP7623943B2 (ja)	2018-11-30	2025-01-29	カイメラセラピューティクス，インコーポレイテッド	Ｉｒａｋ分解剤およびそれらの使用
WO2020112937A1 (en)	2018-11-30	2020-06-04	Nimbus Lakshmi, Inc.	Tyk2 inhibitors and uses thereof
CN111320633B (zh) *	2018-12-14	2022-09-27	中国医药研究开发中心有限公司	吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途
EP3670659A1 (en)	2018-12-20	2020-06-24	Abivax	Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
US20220040324A1 (en)	2018-12-21	2022-02-10	Daiichi Sankyo Company, Limited	Combination of antibody-drug conjugate and kinase inhibitor
WO2020154474A1 (en)	2019-01-23	2020-07-30	Nimbus Lakshmi, Inc.	Tyk2 inhibitors and uses thereof
AU2019426113B2 (en) *	2019-01-30	2022-06-16	Felicamed Biotechnology Co., Ltd.	JAK inhibitor and preparation method therefor
WO2020163431A1 (en)	2019-02-05	2020-08-13	Teva Pharmaceuticals International Gmbh	Crystalline solid forms of baricitinib
WO2020165600A1 (en)	2019-02-14	2020-08-20	Bicycletx Limited	Bicyclic peptide ligand sting conjugates and uses thereof
WO2020173364A1 (zh) *	2019-02-27	2020-09-03	四川科伦博泰生物医药股份有限公司	以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途
JP7248256B2 (ja)	2019-03-14	2023-03-29	上海華匯拓医薬科技有限公司	Ｊａｋキナーゼ阻害剤及びその調製方法、並びにその医薬分野での使用
WO2020188015A1 (en)	2019-03-21	2020-09-24	Onxeo	A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020201753A1 (en)	2019-04-02	2020-10-08	Bicycletx Limited	Bicycle toxin conjugates and uses thereof
AU2020253633A1 (en)	2019-04-05	2021-11-04	Kymera Therapeutics, Inc.	STAT degraders and uses thereof
EP3725305A1 (en)	2019-04-17	2020-10-21	Zentiva K.S.	Pharmaceutical composition containing baricitinib hydrobromide
KR20210141634A (ko) *	2019-04-24	2021-11-23	엘랑코 유에스 인코포레이티드	7h-피롤로[2,3-d]피리미딘 jak-억제제
CN110028509B (zh) *	2019-05-27	2020-10-09	上海勋和医药科技有限公司	作为选择性jak2抑制剂的吡咯并嘧啶类化合物、其合成方法及用途
BR112021024224A2 (pt)	2019-05-31	2022-04-26	Ikena Oncology Inc	Inibidores de tead e usos dos mesmos
CN110256441A (zh) *	2019-06-24	2019-09-20	江苏君若医药有限公司	一种巴瑞克替尼的制备方法
TWI862640B (zh)	2019-07-30	2024-11-21	英商拜西可泰克斯有限公司	異質雙環肽複合物
EP3771715A1 (en)	2019-08-02	2021-02-03	Zaklady Farmaceutyczne "Polpharma" S.A.	Crystalline forms of baricitinib
EP3771716A1 (en)	2019-08-02	2021-02-03	Zaklady Farmaceutyczne "Polpharma" S.A.	Low hygroscopic amorphous form of baricitinib
WO2021050992A1 (en)	2019-09-11	2021-03-18	Vincere Biosciences, Inc.	Usp30 inhibitors and uses thereof
PH12022550605A1 (en)	2019-09-13	2023-09-25	Nimbus Saturn Inc	Hpk1 antagonists and uses thereof
JP2022551649A (ja)	2019-10-10	2022-12-12	インサイト・コーポレイション	移植片対宿主病のバイオマーカー
CN110683978A (zh) *	2019-10-30	2020-01-14	西安医学院	一种3-腈基亚甲基氮杂环丁烷-1-碳酸叔丁酯的制备方法
EP4051259A4 (en)	2019-11-01	2023-11-22	Navitor Pharmaceuticals, Inc.	Methods of treatment using an mtorc1 modulator
WO2021089791A1 (en)	2019-11-08	2021-05-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
KR20220107213A (ko)	2019-11-22	2022-08-02	인사이트 코포레이션	Alk2 억제제 및 jak2 억제제를 포함하는 병용 요법
CN115209897A (zh)	2019-12-05	2022-10-18	安纳库利亚治疗公司	雷帕霉素类似物及其用途
EP4076524A4 (en)	2019-12-17	2023-11-29	Kymera Therapeutics, Inc.	IRAQ DEGRADERS AND USES THEREOF
KR20220145325A (ko)	2019-12-17	2022-10-28	카이메라 쎄라퓨틱스 인코포레이티드	Irak 분해제 및 이의 용도
AU2020405549A1 (en)	2019-12-19	2022-08-11	Liminal Biosciences Limited	Cycloalkyl-containing carboxylic acids and uses thereof
CN115297931A (zh)	2019-12-23	2022-11-04	凯麦拉医疗公司	Smarca降解剂和其用途
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
CA3166908A1 (en)	2020-02-05	2021-08-12	Daniel Kenneth BONNER	Lipid prodrugs of neurosteroids
MX2022010944A (es)	2020-03-03	2022-11-09	Pic Therapeutics Inc	Inhibidores del factor de iniciacion de traduccion eucariotica 4e (eif4e) y sus usos.
JP2023518423A (ja)	2020-03-19	2023-05-01	カイメラセラピューティクス，インコーポレイテッド	Ｍｄｍ２分解剤およびそれらの使用
US20230218644A1 (en)	2020-04-16	2023-07-13	Som Innovation Biotech, S.A.	Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN111362853A (zh) *	2020-04-27	2020-07-03	安徽大学	一种3-氧杂氮杂环丁烷-1-羧酸叔丁酯的制备方法
CN113582901A (zh) *	2020-05-01	2021-11-02	浙江瑞博制药有限公司	一种氧化反应氧化醇制备醛或酮的方法
TW202210471A (zh)	2020-06-02	2022-03-16	美商英塞特公司	製備ｊａｋ１抑制劑之方法
TW202210483A (zh)	2020-06-03	2022-03-16	美商凱麥拉醫療公司	Irak降解劑之結晶型
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
EP4161521A4 (en)	2020-06-03	2024-07-10	Kymera Therapeutics, Inc.	DEUTERED IRAQ DEGRADERS AND USES THEREOF
CN111704617B (zh) *	2020-06-15	2022-08-23	嘉兴特科罗生物科技有限公司	一种小分子化合物
US11753413B2 (en)	2020-06-19	2023-09-12	Incyte Corporation	Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
WO2021257857A1 (en)	2020-06-19	2021-12-23	Incyte Corporation	Naphthyridinone compounds as jak2 v617f inhibitors
WO2022006456A1 (en)	2020-07-02	2022-01-06	Incyte Corporation	Tricyclic pyridone compounds as jak2 v617f inhibitors
MX2023000056A (es)	2020-07-02	2023-04-12	Incyte Corp	Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f).
CN111999400B (zh) *	2020-07-15	2022-07-01	安徽联创生物医药股份有限公司	一种用hplc分离测定巴瑞替尼原料药杂质的方法
CN111875534B (zh) *	2020-08-10	2022-06-17	烟台大学	1,8-二甲酰基咔唑的安全高效制备方法
CN111848491B (zh) *	2020-08-10	2022-06-17	烟台大学	1-甲酰基咔唑的制备方法
JP2023538906A (ja)	2020-08-17	2023-09-12	バイシクルティーエクス・リミテッド	ネクチン－４に特異的な二環コンジュゲート及びその使用
EP4200300A1 (en)	2020-08-18	2023-06-28	Incyte Corporation	Process and intermediates for preparing a jak inhibitor
US11897889B2 (en)	2020-08-18	2024-02-13	Incyte Corporation	Process and intermediates for preparing a JAK1 inhibitor
WO2022046989A1 (en)	2020-08-27	2022-03-03	Incyte Corporation	Tricyclic urea compounds as jak2 v617f inhibitors
US20230404925A1 (en)	2020-10-23	2023-12-21	Elanco Us Inc.	Jak inhibitors having a specific particle size distribution
CN114437079B (zh) *	2020-10-30	2024-11-01	杭州邦顺制药有限公司	吡咯嘧啶五元氮杂环化合物的晶型
WO2022120353A1 (en)	2020-12-02	2022-06-09	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
EP4255895A1 (en)	2020-12-02	2023-10-11	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
MX2023006542A (es)	2020-12-08	2023-08-25	Incyte Corp	Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo.
EP4263559A1 (en)	2020-12-18	2023-10-25	Boehringer Ingelheim Animal Health USA Inc.	Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
WO2022140231A1 (en)	2020-12-21	2022-06-30	Incyte Corporation	Deazaguaine compounds as jak2 v617f inhibitors
CN116867758A (zh)	2020-12-30	2023-10-10	凯麦拉医疗公司	Irak降解剂和其用途
EP4288430A1 (en)	2021-02-02	2023-12-13	Liminal Biosciences Limited	Gpr84 antagonists and uses thereof
CN117098757A (zh)	2021-02-02	2023-11-21	里米诺生物科学有限公司	Gpr84拮抗剂和其用途
CN114907354B (zh) *	2021-02-07	2024-04-09	南京知和医药科技有限公司	一种磺酰胺类多环化合物及其制备方法与用途
US12171768B2 (en)	2021-02-15	2024-12-24	Kymera Therapeutics, Inc.	IRAK4 degraders and uses thereof
WO2022174269A1 (en)	2021-02-15	2022-08-18	Kymera Therapeutics, Inc.	Irak4 degraders and uses thereof
AR125273A1 (es)	2021-02-25	2023-07-05	Incyte Corp	Lactamas espirocíclicas como inhibidores de jak2 v617f
CN118459504A (zh) *	2021-02-26	2024-08-09	南京知和医药科技有限公司	一种巴瑞替尼衍生物及其制备方法与用途
US11926625B2 (en)	2021-03-05	2024-03-12	Nimbus Saturn, Inc.	HPK1 antagonists and uses thereof
JP2024513011A (ja)	2021-03-29	2024-03-21	ニンバスサターン，インコーポレイテッド	Ｈｐｋ１アンタゴニスト及びその使用
WO2022221866A1 (en)	2021-04-16	2022-10-20	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
BR112023023223A2 (pt)	2021-05-07	2024-01-30	Kymera Therapeutics Inc	Degradadores de cdk2 e usos dos mesmos
WO2023288197A1 (en)	2021-07-12	2023-01-19	Incyte Corporation	Process and intermediates for preparing baricitinib
EP4376844A1 (en)	2021-07-30	2024-06-05	Eli Lilly and Company	Treatment of hand eczema with baricitinib
CN118019739A (zh)	2021-08-25	2024-05-10	皮克医疗公司	Eif4e抑制剂及其用途
TW202315621A (zh)	2021-08-25	2023-04-16	美商皮克醫療公司	Ｅｉｆ４ｅ抑制劑及其用途
CN118302168A (zh)	2021-10-29	2024-07-05	凯麦拉医疗公司	Irak4降解剂和其制备
CN114373808B (zh) *	2021-11-26	2023-11-10	江苏科来材料科技有限公司	一种高效晶硅电池
WO2023114984A1 (en)	2021-12-17	2023-06-22	Ikena Oncology, Inc.	Tead inhibitors and uses thereof
CN114149437A (zh) *	2021-12-24	2022-03-08	安徽大学	一种吡咯并嘧啶五元氮杂环衍生物及其制备方法和用途
JP2025504059A (ja)	2022-01-31	2025-02-06	カイメラセラピューティクス，インコーポレイテッド	Ｉｒａｋデグレーダー及びその使用
WO2023173053A1 (en)	2022-03-10	2023-09-14	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
WO2023173057A1 (en)	2022-03-10	2023-09-14	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
EP4493558A1 (en)	2022-03-17	2025-01-22	Incyte Corporation	Tricyclic urea compounds as jak2 v617f inhibitors
WO2023194842A1 (en)	2022-04-05	2023-10-12	Unichem Laboratories Limited	Substituted tricyclic compounds and their use in rheumatoid arthritis
WO2023211889A1 (en)	2022-04-25	2023-11-02	Ikena Oncology, Inc.	Polymorphic compounds and uses thereof
AU2023276599A1 (en)	2022-05-25	2024-12-05	Ikena Oncology, Inc.	Mek inhibitors and uses thereof
CN117384163A (zh) *	2022-07-05	2024-01-12	盛世泰科生物医药技术(苏州)股份有限公司	一种含偕二氟基的化合物及其制备方法和用途
TW202415650A (zh)	2022-08-02	2024-04-16	英商利米那生物科技有限公司	芳基-三唑基及相關gpr84拮抗劑及其用途
TW202416972A (zh)	2022-08-02	2024-05-01	英商利米那生物科技有限公司	經取代之吡啶酮gpr84拮抗劑及其用途
WO2024028363A1 (en)	2022-08-02	2024-02-08	Liminal Biosciences Limited	Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
CN115181103B (zh) *	2022-08-16	2023-11-07	上海博悦生物科技有限公司	一种巴瑞替尼的制备方法
TW202430148A (zh)	2022-11-22	2024-08-01	美商皮克醫療公司	ｅＩＦ４Ｅ抑制劑及其用途
CN118255769A (zh) *	2022-12-28	2024-06-28	格格巫（珠海）生物科技有限公司	一种立体异构体的制备方法及中间体
WO2024193496A1 (zh) *	2023-03-17	2024-09-26	北京普祺医药科技股份有限公司	吡咯并嘧啶化合物或其可药用盐的制备方法
CN116444529B (zh) *	2023-06-16	2023-12-05	药康众拓(江苏)医药科技有限公司	一种氘代氮杂环丁烷类jak抑制剂及其用途

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3036390A1 (de)	1980-09-26	1982-05-13	Troponwerke GmbH & Co KG, 5000 Köln	Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen
US4548990A (en)	1983-08-15	1985-10-22	Ciba-Geigy Corporation	Crosslinked, porous polymers for controlled drug delivery
US5521184A (en)	1992-04-03	1996-05-28	Ciba-Geigy Corporation	Pyrimidine derivatives and processes for the preparation thereof
KR19990028709A (ko)	1995-07-05	1999-04-15	미리암 디. 메코너헤이	살진균 피리미디논
DK0836605T3 (da)	1995-07-06	2002-05-13	Novartis Ag	Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
US6232320B1 (en)	1998-06-04	2001-05-15	Abbott Laboratories	Cell adhesion-inhibiting antiinflammatory compounds
BR9910864A (pt)	1998-06-04	2002-02-05	Abbott Lab	Compostos anti-inflamatórios para inibição de aderência celular
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
EP1087970B1 (en)	1998-06-19	2004-04-28	Pfizer Products Inc.	PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS
BR9912938B1 (pt)	1998-08-11	2011-06-28		derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
US6133031A (en)	1999-08-19	2000-10-17	Isis Pharmaceuticals Inc.	Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en)	1999-03-06	1999-04-28	Zeneca Ltd	Chemical compounds
AU3565999A (en)	1999-04-16	2000-11-02	Coelacanth Chemical Corporation	Synthesis of azetidine derivatives
ATE380031T1 (de)	1999-12-10	2007-12-15	Pfizer Prod Inc	Pyrrolo 2,3-d pyrimidinderivate enthaltende zusammensetzungen
NZ519121A (en)	1999-12-24	2004-05-28	Aventis Pharma Ltd	Azaindoles useful as Syk kinase inhibitors
GB0004890D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
US6335342B1 (en)	2000-06-19	2002-01-01	Pharmacia & Upjohn S.P.A.	Azaindole derivatives, process for their preparation, and their use as antitumor agents
ATE465756T1 (de)	2000-06-23	2010-05-15	Mitsubishi Tanabe Pharma Corp	Antitumoreffekt-verstärker
ES2257410T3 (es)	2000-06-26	2006-08-01	Pfizer Products Inc.	Compuestos de pirrolo(2,3-d)pirimidina como agentes inmunosupresores.
NZ522783A (en)	2000-06-28	2004-07-30	Smithkline Beecham P	Wet milling process for pharmaceuticals with agitator or chamber having nylon with internal lubricant
GB0100622D0 (en)	2001-01-10	2001-02-21	Vernalis Res Ltd	Chemical compounds V111
WO2002060492A1 (en)	2001-01-30	2002-08-08	Cytopia Pty Ltd	Methods of inhibiting kinases
US7301023B2 (en)	2001-05-31	2007-11-27	Pfizer Inc.	Chiral salt resolution
CA2455181C (en)	2001-08-01	2010-04-06	Merck & Co., Inc.	Benzimidazo[4,5-f]isoquinolinone derivatives
CN100391958C (zh)	2001-09-19	2008-06-04	安万特医药股份有限公司	化合物
HU230798B1 (hu)	2001-10-30	2018-06-28	Novartis Ag	Staurosporin-származékok mint az FLT3 receptor tirozin-kináz aktivitás inhibitorai
GT200200234A (es)	2001-12-06	2003-06-27		Compuestos cristalinos novedosos
TW200403058A (en)	2002-04-19	2004-03-01	Bristol Myers Squibb Co	Heterocyclo inhibitors of potassium channel function
US20040019066A1 (en) *	2002-05-06	2004-01-29	Institut Pasteur	Methionine salvage pathway in bacillus
JP2005532313A (ja)	2002-05-07	2005-10-27	コントロール・デリバリー・システムズ・インコーポレイテッド	薬物送達装置の形成方法
AR037647A1 (es)	2002-05-29	2004-12-01	Novartis Ag	Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en)	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
JPWO2004007472A1 (ja)	2002-07-10	2005-11-17	小野薬品工業株式会社	Ｃｃｒ４アンタゴニストおよびその医薬用途
JP4688498B2 (ja)	2002-11-04	2011-05-25	バーテックスファーマシューティカルズインコーポレイテッド	Ｊａｋインヒビターとしてのヘテロアリール−ピリミジン誘導体
AR042052A1 (es)	2002-11-15	2005-06-08	Vertex Pharma	Diaminotriazoles utiles como inhibidores de proteinquinasas
AU2003276591A1 (en)	2002-11-26	2004-06-18	Pfizer Products Inc.	Method of treatment of transplant rejection
UA80767C2 (en)	2002-12-20	2007-10-25	Pfizer Prod Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
US7407962B2 (en)	2003-02-07	2008-08-05	Vertex Pharmaceuticals Incorporated	Heteroaryl compounds useful as inhibitors or protein kinases
GB0305929D0 (en)	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
SE0301373D0 (sv)	2003-05-09	2003-05-09	Astrazeneca Ab	Novel compounds
SE0301372D0 (sv)	2003-05-09	2003-05-09	Astrazeneca Ab	Novel compounds
US20050043346A1 (en)	2003-08-08	2005-02-24	Pharmacia Italia S.P.A.	Pyridylpyrrole derivatives active as kinase inhibitors
AR045944A1 (es)	2003-09-24	2005-11-16	Novartis Ag	Derivados de isoquinolina 1.4-disustituidas
MXPA06005882A (es)	2003-11-25	2006-06-27	Pfizer Prod Inc	Metodo de tratamiento de la aterosclerosis.
KR20060096153A (ko)	2003-12-17	2006-09-07	화이자 프로덕츠 인코포레이티드	이식 거부 치료용 피롤로[2,3-ｄ]피리미딘 화합물
US20050187389A1 (en)	2004-01-13	2005-08-25	Ambit Biosciences Corporation	Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
EP2786995A1 (en)	2004-03-30	2014-10-08	Vertex Pharmaceuticals Incorporated	Azaindoles useful as inhibitors of JAK and other protein kinases
EP1750727A2 (en)	2004-04-23	2007-02-14	Exelixis, Inc.	Kinase modulators and methods of use
WO2005105814A1 (en)	2004-04-28	2005-11-10	Incyte Corporation	Tetracyclic inhibitors of janus kinases
WO2005105988A2 (en)	2004-04-28	2005-11-10	Vertex Pharmaceuticals Incorporated	Crystal structure of human jak3 kinase domain complex and binding pockets thereof
US20090163523A1 (en)	2004-05-03	2009-06-25	Philip Lake	Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
MXPA06013250A (es)	2004-05-14	2007-02-28	Abbott Lab	Inhibidores de quinasa como agentes terapeuticos.
PE20060426A1 (es)	2004-06-02	2006-06-28	Schering Corp	DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
EP1760071A4 (en)	2004-06-23	2008-03-05	Ono Pharmaceutical Co	COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
WO2006013114A1 (en)	2004-08-06	2006-02-09	Develogen Aktiengesellschaft	Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
MY179032A (en)	2004-10-25	2020-10-26	Cancer Research Tech Ltd	Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es)	2004-10-25	2006-05-31	Astex Therapeutics Ltd	Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
AU2005309019A1 (en)	2004-11-24	2006-06-01	Novartis Ag	Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
AR054416A1 (es)	2004-12-22	2007-06-27	Incyte Corp	Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
ES2320487T3 (es)	2005-02-03	2009-05-22	Vertex Pharmaceuticals, Inc.	Pirrolopirimidinas utiles como inhibidores de proteina quinasas.
GB0510139D0 (en)	2005-05-18	2005-06-22	Addex Pharmaceuticals Sa	Novel compounds B1
EP2354140A1 (en)	2005-05-20	2011-08-10	Vertex Pharmaceuticals Incorporated	Pyrrolopyridines useful as inhibitors of protein kinase
WO2006136823A1 (en)	2005-06-21	2006-12-28	Astex Therapeutics Limited	Heterocyclic containing amines as kinase b inhibitors
US20070049591A1 (en)	2005-08-25	2007-03-01	Kalypsys, Inc.	Inhibitors of MAPK/Erk Kinase
US20070149506A1 (en)	2005-09-22	2007-06-28	Arvanitis Argyrios G	Azepine inhibitors of Janus kinases
EP2532667A1 (en)	2005-09-30	2012-12-12	Vertex Pharmaceuticals Incorporated	Deazapurines useful as inhibitors of janus kinases
LT2426129T (lt)	2005-12-13	2017-02-10	Incyte Holdings Corporation	Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
JP2009521504A (ja)	2005-12-22	2009-06-04	スミスクライン・ビーチャム・コーポレイション	Ａｋｔ活性阻害剤
UA95940C2 (uk)	2006-01-17	2011-09-26	Вертекс Фармасьютикалс Інкорпорейтед	Азаіндоли як інгібітори кіназ януса
AU2007235487A1 (en)	2006-04-05	2007-10-18	Vertex Pharmaceuticals Incorporated	Deazapurines useful as inhibitors of janus kinases
TW200805992A (en) *	2006-07-04	2008-01-16	Benq Corp	Method and apparatus for barring short message
WO2008079965A1 (en)	2006-12-22	2008-07-03	Incyte Corporation	Substituted heterocycles as janus kinase inhibitors
CL2008001709A1 (es)	2007-06-13	2008-11-03	Incyte Corp	Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
RS54878B1 (sr)	2007-06-13	2016-10-31	Incyte Holdings Corp	Kristalne soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropionitril

2009
- 2009-03-10 JP JP2010550808A patent/JP5275371B2/ja active Active
- 2009-03-10 MY MYPI2010004226A patent/MY165582A/en unknown
- 2009-03-10 CN CN201410017280.7A patent/CN103788098A/zh active Pending
- 2009-03-10 EA EA201071057A patent/EA017218B1/ru active Protection Beyond IP Right Term
- 2009-03-10 EP EP09718650.6A patent/EP2288610B8/en active Active
- 2009-03-10 SG SG2013044821A patent/SG191660A1/en unknown
- 2009-03-10 CN CN200980116857.7A patent/CN102026999B/zh active Active
- 2009-03-10 US US12/401,348 patent/US8158616B2/en active Active
- 2009-03-10 AU AU2009223640A patent/AU2009223640B2/en active Active
- 2009-03-10 PT PT97186506T patent/PT2288610T/pt unknown
- 2009-03-10 WO PCT/US2009/036635 patent/WO2009114512A1/en active Application Filing
- 2009-03-10 BR BRPI0909040A patent/BRPI0909040B8/pt active IP Right Grant
- 2009-03-10 ES ES09718650.6T patent/ES2602577T3/es active Active
- 2009-03-10 HU HUE09718650A patent/HUE029767T2/en unknown
- 2009-03-10 UA UAA201010917A patent/UA101493C2/ru unknown
- 2009-03-10 KR KR1020107020309A patent/KR101240882B1/ko active Protection Beyond IP Right Term
- 2009-03-10 RS RS20160911A patent/RS55263B1/sr unknown
- 2009-03-10 KR KR1020127020848A patent/KR20120108042A/ko not_active Application Discontinuation
- 2009-03-10 TW TW098107750A patent/TWI444382B/zh active
- 2009-03-10 PL PL09718650T patent/PL2288610T3/pl unknown
- 2009-03-10 LT LTEP09718650.6T patent/LT2288610T/lt unknown
- 2009-03-10 MX MX2010010012A patent/MX2010010012A/es active IP Right Grant
- 2009-03-10 NZ NZ587928A patent/NZ587928A/xx unknown
- 2009-03-10 CA CA2718271A patent/CA2718271C/en active Active
- 2009-03-10 DK DK09718650.6T patent/DK2288610T3/en active
- 2009-03-10 SI SI200931524A patent/SI2288610T1/sl unknown
- 2009-03-11 AR ARP090100869A patent/AR070828A1/es active IP Right Grant
- 2009-03-11 PE PE2009000355A patent/PE20091712A1/es active IP Right Grant
- 2009-03-11 PA PA20098819201A patent/PA8819201A1/es unknown
- 2009-03-11 UY UY31705A patent/UY31705A1/es active IP Right Grant
- 2009-03-11 CL CL2009000576A patent/CL2009000576A1/es unknown
- 2009-03-11 PE PE2013000889A patent/PE20140099A1/es not_active Application Discontinuation
2010
- 2010-08-23 ZA ZA2010/06000A patent/ZA201006000B/en unknown
- 2010-09-03 HN HN2010001761A patent/HN2010001761A/es unknown
- 2010-09-06 IL IL208023A patent/IL208023A/en active Protection Beyond IP Right Term
- 2010-09-08 TN TNP2010000415A patent/TN2010000415A1/fr unknown
- 2010-09-08 DO DO2010000270A patent/DOP2010000270A/es unknown
- 2010-09-10 EC EC2010010475A patent/ECSP10010475A/es unknown
- 2010-09-10 SV SV2010003662A patent/SV2010003662A/es unknown
- 2010-09-24 CO CO10118687A patent/CO6290658A2/es active IP Right Grant
- 2010-10-11 MA MA33236A patent/MA32219B1/fr unknown
2011
- 2011-03-29 HK HK11103140.0A patent/HK1149005A1/zh unknown
- 2011-12-09 US US13/315,750 patent/US8420629B2/en active Active
2013
- 2013-02-11 DO DO2013000036A patent/DOP2013000036A/es unknown
- 2013-03-13 JP JP2013050687A patent/JP2013155179A/ja not_active Withdrawn
- 2013-03-29 US US13/853,475 patent/US20130225556A1/en not_active Abandoned
2016
- 2016-10-25 HR HRP20161390TT patent/HRP20161390T1/hr unknown
- 2016-10-31 CY CY20161101100T patent/CY1118176T1/el unknown
2017
- 2017-07-07 NL NL300886C patent/NL300886I2/nl unknown
- 2017-07-10 CY CY2017024C patent/CY2017024I2/el unknown
- 2017-07-11 NO NO2017033C patent/NO2017033I1/no unknown
- 2017-07-11 LU LU00027C patent/LUC00027I2/fr unknown
- 2017-07-14 LT LTPA2017023C patent/LTC2288610I2/lt unknown
- 2017-07-18 HU HUS1700031C patent/HUS1700031I1/hu unknown

Also Published As

Publication number	Publication date
JP5275371B2 (ja)	2013-08-28
EP2288610B1 (en)	2016-08-31
LTC2288610I2 (lt)	2019-02-25
US20130225556A1 (en)	2013-08-29
BRPI0909040B8 (pt)	2021-05-25
CN102026999B (zh)	2014-03-05
PE20091712A1 (es)	2009-11-21
PL2288610T3 (pl)	2017-12-29
KR101240882B1 (ko)	2013-03-11
ES2602577T3 (es)	2017-02-21
HK1149005A1 (zh)	2011-09-23
HN2010001761A (es)	2013-09-02
MA32219B1 (fr)	2011-04-01
JP2013155179A (ja)	2013-08-15
JP2011514909A (ja)	2011-05-12
US20120077798A1 (en)	2012-03-29
MY165582A (en)	2018-04-05
CL2009000576A1 (es)	2009-06-19
BRPI0909040A8 (pt)	2017-12-12
US8420629B2 (en)	2013-04-16
LUC00027I1 (sl)	2017-07-12
NO2017033I2 (no)	2017-07-11
EA201071057A1 (ru)	2011-02-28
PA8819201A1 (es)	2010-07-27
TW200942545A (en)	2009-10-16
NL300886I2 (nl)	2017-10-24
AU2009223640A1 (en)	2009-09-17
CO6290658A2 (es)	2011-06-20
DOP2010000270A (es)	2010-10-15
LT2288610T (lt)	2016-12-12
MX2010010012A (es)	2010-10-20
HUS1700031I1 (hu)	2017-09-28
KR20120108042A (ko)	2012-10-04
LUC00027I2 (sl)	2017-09-25
CY2017024I1 (el)	2017-11-14
BRPI0909040A2 (sl)	2017-09-19
BRPI0909040B1 (pt)	2019-10-22
HRP20161390T1 (hr)	2016-12-02
EP2288610B8 (en)	2016-10-12
US20090233903A1 (en)	2009-09-17
RS55263B1 (sr)	2017-02-28
US8158616B2 (en)	2012-04-17
CA2718271C (en)	2014-05-06
CA2718271A1 (en)	2009-09-17
ECSP10010475A (es)	2010-10-30
PT2288610T (pt)	2016-10-17
CY1118176T1 (el)	2017-06-28
KR20100121657A (ko)	2010-11-18
ZA201006000B (en)	2012-01-25
CN102026999A (zh)	2011-04-20
TN2010000415A1 (en)	2011-12-29
HUE029767T2 (en)	2017-04-28
SI2288610T1 (sl)	2016-11-30
NO2017033I1 (no)	2017-07-11
SG191660A1 (en)	2013-07-31
WO2009114512A1 (en)	2009-09-17
AU2009223640B2 (en)	2013-07-04
AR070828A1 (es)	2010-05-05
CY2017024I2 (el)	2017-11-14
LTPA2017023I1 (lt)	2017-08-10
EP2288610A1 (en)	2011-03-02
CN103788098A (zh)	2014-05-14
DK2288610T3 (en)	2016-11-28
TWI444382B (zh)	2014-07-11
SV2010003662A (es)	2011-03-17
IL208023A (en)	2015-08-31
UY31705A1 (es)	2009-08-03
UA101493C2 (ru)	2013-04-10
EA017218B1 (ru)	2012-10-30
IL208023A0 (en)	2010-12-30
PE20140099A1 (es)	2014-02-06
DOP2013000036A (es)	2013-03-15

Publication	Publication Date	Title
NZ587928A (en)	2012-08-31	Azetidine and cyclobutane derivatives as jak inhibitors
NZ602313A (en)	2014-08-29	Piperidin-4-yl azetidine derivatives as jak1 inhibitors
NZ590320A (en)	2012-12-21	Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
US9440957B2 (en)	2016-09-13	Compounds and compositions for modulating EGFR Activity
TWI652261B (zh)	2019-03-01	新穎胺基嘧啶衍生物
KR101626681B1 (ko)	2016-06-01	피라졸로[3,4-d]피리미딘 화합물 및 pde2 억제제 및/또는 cyp3a4 억제제로서의 이의 용도
NZ702041A (en)	2016-03-31	Heterocyclic containing entities, compositions and methods
NZ590283A (en)	2012-11-30	Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors
ES2666155T3 (es)	2018-05-03	Moduladores de P2X7
NZ596479A (en)	2014-01-31	N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
JP2014516074A5 (sl)	2015-07-09
US8703946B2 (en)	2014-04-22	Substituted pyrazolo[1,5-A]pyrazine compounds as allosteric modulators of mGluR5 receptors
JP2013523884A5 (sl)	2014-05-22
UA111854C2 (uk)	2016-06-24	Способи і проміжні сполуки для отримання інгібіторів jak
IL202429A0 (en)	2010-06-30	Metabolites of the janus kinase inhibiting (r)-3-(4-(7h-pyrrolo[2,3-d] pyrimidin-4-yl)1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Lind et al.	2017	Structural basis of subunit selectivity for competitive NMDA receptor antagonists with preference for GluN2A over GluN2B subunits
EP3712153A1 (en)	2020-09-23	Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
EA032100B1 (ru)	2019-04-30	Полифторзамещенное соединение в качестве ингибитора тирозинкиназы брутона (btk)
EA018266B1 (ru)	2013-06-28	ПОЛИЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 2-АРИЛ-6-ФЕНИЛИМИДАЗО[1,2-a]ПИРИДИНОВ, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ
PE20090964A1 (es)	2009-08-15	Derivados de pirrolo[2,3-d]pirimidina como inhibidores de proteina quinasa b
US20150152083A1 (en)	2015-06-04	Compounds and Compositions for Modulating EGFR Activity
US20130345205A1 (en)	2013-12-26	Substituted bicyclic aralkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
EP2955181A1 (en)	2015-12-16	Tricyclic pyrrolopyridine compound, and jak inhibitor
AR104918A1 (es)	2017-08-23	Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo
WO2013192346A9 (en)	2014-12-18	Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mglur5 receptors

Legal Events

Date	Code	Title	Description
2013-03-28	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 10 MAR 2016 BY AJ PARK Effective date: 20130315
2015-09-25	ASS	Change of ownership	Owner name: INCYTE HOLDING, US Effective date: 20150910
2016-02-26	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2017 BY THOMSON REUTERS Effective date: 20160217
2017-02-24	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2018 BY THOMSON REUTERS Effective date: 20170221
2018-02-23	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2019 BY THOMSON REUTERS Effective date: 20180217
2019-02-22	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2020 BY THOMSON REUTERS Effective date: 20190216
2020-02-28	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2021 BY THOMSON REUTERS Effective date: 20200205
2021-02-26	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2022 BY ANAQUA SERVICES Effective date: 20210217
2022-02-25	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2023 BY ANAQUA SERVICES Effective date: 20220218
2023-02-24	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2024 BY ANAQUA SERVICES Effective date: 20230222
2024-02-23	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2025 BY ANAQUA SERVICES Effective date: 20240220